Platelet-derived growth factor (PDGF) is an important serum regulator of erythropoiesis in vitro. We have now obtained evidence suggesting that PDGF-like molecules may also modulate erythropoiesis in vivo. Western blot analysis of cytoplasmic extracts from Rauscher murine erythroleukemia cells and phenylhydrazine-treated mouse splenic erythroid cells revealed the presence of several PDGF-like proteins. The presence of PDGF-like proteins in the cytoplasm of these two erythroid cell types was confirmed by immunohistochemical staining. Using a serum-free biologic assay, PDGF-like biological activity was found in cell lysates and conditioned medium of both Rauscher cells and phenylhydrazine-treated mouse erythroid cells. Subcellular localization experiments revealed the biological activity to be concentrated in the cytosolic fraction. Using a series of antibodies to hematopoietic growth factors we demonstrated that PDGF-like biological activity was specifically immunoprecipitated by both monoclonal and polyclonal anti-human PDGF antibodies but not by antibodies to burst-promoting activity, granulocyte-macrophage colonystimulating factor, IL-3, or erythropoietin. Taken together, the data are consistent with the hypothesis that PDGF-like molecules play a role in the regulation of mammalian erythropoiesis in vivo. (J. Clin. Invest. 1990. 85:40-46.) erythropoiesis platelet-derived growth factor -progenitors * Rauscher
Introduction
The growth of erythroid progenitors in vitro is stimulated by platelet-derived growth factor (PDGF; 1).' PDGF may act to stimulate progenitor growth directly by an effect on erythroid progenitors or indirectly by affecting mesenchymal cells which in turn modulate erythropoiesis (2). PDGF-like proteins are 1. Abbreviations used in this paper: BPA, erythroid burst-promoting activity; GM-CSF, granulocyte-macrophage colony-stimulating factor; PDGF, platelet-derived growth factor.
produced by a variety of transformed cell types (3-5). These PDGF-like molecules bind to authentic PDGF receptors and exhibit biological activity. Like the B chain of authentic PDGF, many of these PDGF-like molecules are products of the cellular oncogene c-sis. The production of A-A homodimers by cells has also been reported (6) .
Work by Pappayannopoulou and co-workers (7) and Leary et al. (8) demonstrated that some transformed cell lines with erythroid characteristics either produce PDGF-like molecules constitutively or can be induced to do so. Unpublished data obtained in our laboratory indicated that the erythropoietinresponsive Rauscher murine erythroleukemia cell line (9, 10) produces PDGF-like molecules constitutively. The observations that PDGF can stimulate erythropoiesis and that PDGFlike molecules are produced by transformed cells with erythroid characteristics prompted us to determine whether there is an in vivo correlate to these in vitro observations. The results ofthe present study indicate that the production of PDGF-like molecules accompanies erythropoiesis in vivo and that these molecules may be produced by the erythroid cells themselves.
Methods
Cells. The continuous cell lines Rauscher murine erythroleukemia and K562 (11) were maintained in DMEM containing 10% fetal bovine serum in a humidified atmosphere of 95% air/5% CO2 at 37°C. Normal splenic lymphocytes were obtained from female B6C3F1 mice.
Erythroid cells were obtained from the spleens of mice treated with phenylhydrazine as described (12) . Crude soluble extracts were prepared by homogenizing cells with 70 strokes ofa Dounce homogenizer (ball A) in distilled water followed by centrifugation at 27,000 g for 30 min. Immunohistochemistry. Cells were harvested, washed in serumfree DME, resuspended at a concentration of1 X 106/ml, and centrifuged onto glass slides at 1,500 rpm for5 min (Cytospin 2; Shandon Southern Instruments Inc., Sewickley, PA). The slides were immersed briefly in acetone at room temperature and stored at -20'C. After returning to room temperature the cells were fixed in acetone for 10 min at4VC, equilibrated with 50mM Tris-HCI, pH 7.4, for 5 min, and treated with monospecific anti-PDGF antibodies (1:200) for 1 h in a humidified chamber. Irrelevant goat antibody (recognizing hepatitis B virus) and Tris buffer were used as controls. The slides were washed in 50mM Tris-HCI, 140mM NaCl, pH 7.4, and treated with biotin-conjugated rabbit anti-goat IgG (1:100; Cappel Laboratories, Cochranville, PA) for 30 min. After washing, the slides were treated with alkaline phosphatase-conjugated avidin-biotin complex (ABC-AP Vectastain kit; Vector Laboratories, Inc., Burlingame, CA), washed with Tris Plasma membranes from normal splenic lymphocytes and from the Rauscher and K562 cell lines were isolated by a modification of the method ofJett et al. (14) as previously described (15). Briefly, cells were suspended in Dulbecco's PBS, loaded with glycerol at a final volume of 30%, and lysed with 20 strokes of a Dounce homogenizer in 5 mM Tris-HCI and 2 mM MgCI2, pH 7.4 (buffer C). The homogenate was centrifuged for 10 min at 700 g to remove the nuclei. The nuclear pellet was washed and the supernatants were combined and centrifuged at 3,000 g for 10 min to pellet the mitochondria. The resultant supernatant was centrifuged at 40,000 g for 45 minutes to separate crude plasma membranes from the soluble fraction (cytosol). The crude membranes were suspended in 50% sucrose (wt/vol) in buffer C, overlayered with equal volumes of 40, 30, and 20% sucrose in buffer C, and centrifuged in an SW 41 rotor (Beckman Instruments, Inc., Palo Alto, CA) at 200,000 g for 18 h. Plasma membranes were harvested from the 30-40% sucrose interface, washed once with PBS, and stored at -20°C until analysis.
SDS-PAGE and immunodetection
In addition, plasma membranes and soluble fractions were prepared from nucleated erythroid precursors isolated from spleens of phenylhydrazine-treated mice. Splenocytes were suspended in a hypotonic buffer consisting of 10 mM Tris-HCl, 10 mM KC1, and 1.5 mM MgCl2, pH 7.5, and disrupted with 40 strokes of a tight-fitting Dounce homogenizer (15). To restore isotonicity, 2 M sucrose was added to achieve a final concentration of260 mM. The homogenate was layered over a sucrose gradient of 3 vol 28% (wt/vol) sucrose and 2 vol 50% (wt/vol) sucrose. All sucrose solutions were made in 140 mM NaCl, 2.4 mM MgCl2, and 5 mM Tris-HCI, pH 7.4. The sucrose density gradients were centrifuged at 1 7,000 gin an SW 41 swinging bucket rotor (Beckman Instruments, Inc.) for 40 min. Plasma membranes were harvested from the 28-50% sucrose interface and the soluble fraction (cytosol) was removed from the top of the gradient. The harvested plasma membrane fraction was washed with PBS and pelleted at 15,000 g for 10 min. The pellet was resuspended in a minimal volume of PBS and stored at -20°C until use.
Conditioned medium. Conditioned medium from splenocytes or cell lines was prepared by washing cells three times with serum-free DME followed by incubation in serum-free DME for 16 h at 37°C (5-10 X 105 cells/ml).
Immunoadsorption ofcellularfractions. To determine whether the erythroid growth-promoting activity found in the soluble fraction of Rauscher cells (see Results) was due to the presence of one or more well-characterized hematopoietic growth factors, aliquots of the soluble fractions were preadsorbed with polyclonal anti-erythroid burstpromoting activity (BPA) (16), anti-granulocyte-macrophage colonystimulating factor (GM-CSF), and anti-IL-3 (courtesy of Steve Clark, Genetics Institute, Cambridge, MA), monoclonal anti-erythropoietin (17) , mouse monoclonal anti-PDGF B chain [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The adsorbed supernatants were filter sterilized and added to bone marrow culture. Control immunoadsorptions were performed with GM-CSF alone, GM-CSF plus anti-GM-CSF, IL-3 alone, IL-3 plus anti-IL-3, rabbit IgG, and the soluble fractions of Rauscher and K562 cells alone. Immunoadsorption (rather than neutralization) was used since not all antibody preparations were neutralizing and because S. (Fig. 2) . When stained with Wright's stain, Rauscher cells resemble malignant pronormoblasts (Fig. 2 A) . Essentially all of the cells stained positively with anti-PDGF antibodies (Fig. 2 B) , whereas none ofthe cells were stained by control goat IgG (Fig. 2 C) . Wright's stain of normal spleen cells revealed a population of virtually 100% lymphoid cells (Fig. 2 D) . These cells did not stain positively with anti-PDGF antibodies (Fig. 2 E) or with the control IgG (Fig. 2 F) , supporting the results shown in Fig. 1, lanes A and B, that normal splenocytes do not contain PDGF. In contrast, spleen cells from phenylhydrazine-treated mice were a heterogeneous population consisting of lymphocytes and erythroid cells at various stages of differentiation (Fig. 2 G) . The early erythroid precursors were relatively larger than lymphoid elements and often appeared in clusters. Staining of these spleen cells with anti-PDGF antibodies demonstrated PDGF-like crossreactivity in the cytoplasm of the larger erythroid cells (Fig. 2 H) but not in that of the smaller lymphoid cells. Finally, control IgG did not stain any cells in this population (Fig. 2 I) .
Production of PDGF-like biological activity by Rauscher cells and splenic erythroblasts. To determine whether PDGFlike biological activity was present in and secreted by mouse splenocytes and/or cell lines, we prepared and assayed cell lysates and serum-free medium conditioned by these cells. As shown in Fig. 3 , both lysates and conditioned medium (C.M.) of phenylhydrazine-induced erythroid cells (PHZ) and Rauscher cells (RAU) stimulated BFU-E growth (relative to control, P < 0.05 for each). The degree of stimulation in these studies was comparable to that obtained with authentic human PDGF (1). In contrast, lysates and conditioned medium from normal splenic lymphocytes (L) and K562 cells had no effect. Similar results were obtained when CFU-E proliferation was assessed (not shown). The data indicate that bioactive molecules are produced by Rauscher cells and murine splenic erythroblasts, but not by K562 cells or murine splenic lymphocytes.
Subcellular localization of hematopoietic growth factors. We next asked whether a particular subcellular fraction of Rauscher cells or splenic erythroblasts contained the erythroid growth-promoting activity. We observed that on a per microgram protein basis, erythroid burst stimulatory activity was localized to the cytosolic fraction of Rauscher cells (Fig. 4 A,  closed circles) . Dose-dependent stimulation was observed over a range of 12.5-50 ,g cytosolic protein.
A smaller but nonetheless significant (P < 0.05) increase in the formation of CFU-E-derived colonies was also observed (Fig. 4 B, open  circles) . In comparison, nucleus, mitochondria, endoplasmic reticulum, and membrane fractions expressed less (P < 0.05) or no stimulating activity (Fig. 4) .
The results of adding subcellular fractions derived from splenocytes of phenylhydrazine-treated and normal mice are shown in Fig. 5 . The cytosolic fraction from phenylhydrazinetreated mouse splenocytes strongly enhanced erythroid burst (Fig. 5 A, closed circles) and CFU-E-derived colony formation ( Rauscher cell cytosolic protein (Fig. 4 A) . In contrast, there was no effect of plasma membranes from these cells on either BFU-E or CFU-E proliferation (inverted triangles; P> 0.10 for each). Importantly, there was no effect ofthe cytosolic fraction from normal splenic lymphocytes on early or late progenitor cell proliferation (Fig. 5, B and D) . The data indicate that one or more soluble factors in murine erythroblasts augment erythroid colony formation and that this activity is absent from the cytosol of normal mouse splenic lymphocytes.
Immunologic crossreactivity of the cytosolic growth factor with PDGF. To characterize the nature of the cytosolic bioactive molecules, an attempt was made to immunoadsorb the activity from Rauscher cell cytosolic proteins with antibodies to several hematopoietic growth factors. Both polyclonal antihuman PDGF antibodies and monoclonal anti-PDGF B chain [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] antibody immunoadsorbed the stimulatory activity in a concentration-dependent manner (Fig. 6, circles and  squares) . The results were comparable for both BFU-E and CFU-E stimulatory activities. In contrast, none of the other antibodies tested (anti-BPA, anti-GM-CSF, anti-erythropoietin, and anti-IL-3) immunoadsorbed the activity from Rauscher cell cytosol. The results indicate that factors found in A B The data presented in Fig. 1 are notable for the presence of PDGF-like molecules of several molecular weights. These differences are presumably due to differential amino-and carboxy-terminal processing of the nascent protein, a well-established posttranslational modification that has been shown to result in conversion of the 28-kD c-sis gene product to the 14-kD B chain of authentic PDGF. Since the cytoplasmic mRNA of c-sis found in a variety of cells is 4.3-4.6 kb (thus encoding a theoretical 158-169-kD protein), it seems clear that other processing events are also likely. Niman et al. (18) found a wide variety of PDGF-like molecules, including several > 30 kD, in both simian sarcoma virus-infected (v-sis) and noninfected cells. Proteins of 50-60 kD were common and may be related to the 56-kD species shown in Fig. 1 . The absence of the 13-and 1 5-kD species in splenic erythroid cells (Fig. 1, lane C Rauscher cells (Fig. 1, lane A) presumably reflects different processing events in these two cells types, a finding that is not unexpected ( 18). Phenylhydrazine-induced hemolysis in mice is accompanied by elevated circulating levels of erythropoietin, which in turn induce an expansion of the erythroid compartment in the bone marrow and spleen. In this regard, the action of erythropoietin in regulating red cell production can be considered to be twofold. First, the hormone induces DNA synthesis in and proliferation of erythroid progenitor and precursor cells. Second, erythropoietin induces terminal differentiation of erythroid cells that is characterized by hemoglobin accumulation. The mechanism(s) through which the hormone-receptor interaction triggers these distinct cellular responses is unknown. One possibility is that multiple signals may be induced by a single hormone-receptor event. This motif has been demonstrated with the hormone glucagon, the action of which involves alterations in cyclic nucleotides as well as in phosphoinositol intermediates (26). Our results with PDGF raise the possibility that the proliferative effects of erythropoietin may be mediated in part by the production of biologically active PDGF-like molecules in erythroid cells themselves. Since PDGF has not been reported to have an effect on hemoglobinization of committed erythroid cells, erythropoietininduced production of PDGF-like molecules may serve as one regulatory pathway involved in erythropoietin-dependent cell proliferation. Although this need not be the only means through which erythropoietin exerts a stimulatory effect, it could prove to be an especially effective one since one means of controlling this stimulus would be via regulating the expression of the gene or genes involved. Additional studies with highly purified populations of erythropoietin-responsive progenitor cells will be required to explore this possibility.
The modulation oferythropoiesis by PDGF-like molecules in vivo might be effected by several possible mechanisms, two of which are depicted in Fig. 7 . The first possibility, shown in Fig. 7 A, suggests that erythropoietin induction of the erythroid progenitor stimulates the synthesis and release of one or more PDGF-like proteins. These proteins then modulate growth of the erythroid progenitor directly by an autocrine mechanism. The second possibility, depicted in Fig. 7 
